Abstract
Clonal neoantigens have been identified as a subset of patient specific mutations that can be targeted using a personalised cell therapy approach to treat solid cancer. Process 1 of the VELOSTM manufacturing platform has successfully demonstrated the feasibility of generating clonal neoantigen reactive T cells (cNeT) products for the treatment of advanced NSCLC (NCT04032847) and recurrent or metastatic melanoma (NCT03997474). Here we demonstrate that our next generation VELOSTM Process 2 can generate a significant dose boost of highly potent and reactive CD8+ and CD4+ cNeT for clinical use.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
